Canadian Small Cap Pharma Industry Rises as Concordia International Continues to Fall

Share on Linkedin

We conduct a fundamental analysis of Concordia International, and discuss how it will have troubles paying off its long-term debt

It has been an eventful year for Canadian Pharma companies thus far, headlined by the declines of Valeant Pharmaceuticals International, Inc. (TSX: VRX) and Concordia International Corp. (TSX: CXR). Despite this, Canadian small cap pharma companies are up on average 12.1% YTD, trumping the TSX, which has returned 1.2% thus far. In this report, we discuss some industry highlights, as well as a couple of companies that have performed well so far this year. Finally, we conduct a fundamental analysis of Concordia International, and discuss how it will have troubles paying off its long-term debt.

This Content is Exclusive to Our Members

Login below

Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: